Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK

Zixing Tian, Lianne Kearsley-Fleet, James Galloway, Kath Watson, Mark Lunt, BSRBR-RA Contributors Group, Kimme L. Hyrich

Research output: Contribution to journalArticlepeer-review

Abstract

Objective Janus kinase inhibitors (JAKi) or targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) effectively treat rheumatoid arthritis (RA). However, due to safety concerns, the European Medicines Agency (EMA) published risk minimisation measures limiting JAKi prescription to certain at-risk patients unless no suitable alternative is available. This analysis included patients who had started their first-ever JAKi before EMA measures were published in a large national cohort study to investigate the potential impact of these measures on JAKi prescribing and utilisation in UK.

Method RA patients starting first-ever JAK inhibitor therapy in BSRBR-RA between 13-February-2017 and 31-May-2022 were included. Percentages of patients meeting EMA risk criteria were presented. For at-risk patients, previous number of distinct biological (b) DMARD classes were described.

Result A total of 1341 patients were included, and 80% (N=1075) met ≥1 EMA risk criterion. Of those who met ≥1 risk criterion, 529 patients (49%) had received JAKi as their first or second b/tsDMARD class, whereas 299 (28%) had received ≥3 prior bDMARD classes.

Conclusion Four-in-five RA patients commencing JAKi before the EMA advisory were considered ‘at-risk' with prescribing only advised if there was no suitable alternative. Almost a third of those patients had already received ≥3 bDMARDs classes, and alternative therapies would be very limited for them; meanwhile, suitable alternatives might have existed for the remaining proportion, especially for those who received JAKi as their first or second b/tsDMARD, and re-evaluation of the suitability of their treatment may be needed.
Original languageEnglish
Article numberkeae279
JournalRheumatology
DOIs
Publication statusPublished - 15 May 2024

Keywords

  • JAK inhibitor
  • Rheumatoid arthritis
  • Real-world evidence

Fingerprint

Dive into the research topics of 'Potential impact of European Medicines Agency measures to minimise risk of serious side effects on JAKi prescribing and utilisation in the UK'. Together they form a unique fingerprint.

Cite this